Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Overview of attention for article published in Frontiers in Pharmacology, November 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 23 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 5,783 followers.

New Research: Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma https://t.co/w8VF8SHGEe #pharmacology

16 Nov 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.